N-[2-(4-benzoyl-1-piperazinyl)phenyl]-2-(4-chlorophenoxy) Acetamide is a Novel Inhibitor of Resorptive Bone Loss in Mice

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2020 Dec 28

PMID 33369010

Citations 1

Authors

Zhihao Chen

Eunjin Cho

Mina Ding

Jihyoun Seong

Xiangguo Che

Sunwoo Lee

Byung-Ju Park

Je-Yong Choi

Tae-Hoon Lee

Affiliations

Soon will be listed here.

Abstract

The dynamic balance between bone formation and bone resorption is vital for the retention of bone mass. The abnormal activation of osteoclasts, unique cells that degrade the bone matrix, may result in many bone diseases such as osteoporosis. Osteoporosis, a bone metabolism disease, occurs when extreme osteoclast-mediated bone resorption outstrips osteoblast-related bone synthesis. Therefore, it is of great interest to identify agents that can regulate the activity of osteoclasts and prevent bone loss-induced bone diseases. In this study, we found that N-[2-(4-benzoyl-1-piperazinyl)phenyl]-2-(4-chlorophenoxy) acetamide (PPOAC-Bz) exerted a strong inhibitory effect on osteoclastogenesis. PPOAC-Bz altered the mRNA expressions of several osteoclast-specific marker genes and blocked the formation of mature osteoclasts, suppressing F-actin belt formation and bone resorption activity in vitro. In addition, PPOAC-Bz prevented OVX-induced bone loss in vivo. These findings highlighted the potential of PPOAC-Bz as a prospective drug for the treatment of osteolytic disorders.

Citing Articles

N-[2-(4-benzoyl-1-piperazinyl)phenyl]-2-(4-chlorophenoxy) acetamide is a novel inhibitor of resorptive bone loss in mice.

Chen Z, Cho E, Ding M, Seong J, Che X, Lee S J Cell Mol Med. 2020; 25(3):1425-1438.

PMID: 33369010 PMC: 7875930. DOI: 10.1111/jcmm.16228.

References

Boyle W, Simonet W, Lacey D . Osteoclast differentiation and activation. Nature. 2003; 423(6937):337-42. DOI: 10.1038/nature01658. View

Boyce B, Li J, Xing L, Yao Z . Bone Remodeling and the Role of TRAF3 in Osteoclastic Bone Resorption. Front Immunol. 2018; 9:2263. PMC: 6172306. DOI: 10.3389/fimmu.2018.02263. View

Kim M, Ryu S, Choi J, Min Y, Kim S . Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts. J Cell Physiol. 2009; 221(3):618-28. DOI: 10.1002/jcp.21892. View

Kim K, Lee Y, Hwang H, Sung S, Lee M, Son Y . Betulin Suppresses Osteoclast Formation via Down-Regulating NFATc1. J Clin Med. 2018; 7(6). PMC: 6025465. DOI: 10.3390/jcm7060154. View

Kim J, Kim N . Regulation of NFATc1 in Osteoclast Differentiation. J Bone Metab. 2014; 21(4):233-41. PMC: 4255043. DOI: 10.11005/jbm.2014.21.4.233. View

Feng X, McDonald J . Disorders of bone remodeling. Annu Rev Pathol. 2010; 6:121-45. PMC: 3571087. DOI: 10.1146/annurev-pathol-011110-130203. View

Kim K, Lee S, Kim J, Choi Y, Kim N . NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol Endocrinol. 2007; 22(1):176-85. PMC: 2725751. DOI: 10.1210/me.2007-0237. View

Wang Q, Yao L, Xu K, Jin H, Chen K, Wang Z . Madecassoside inhibits estrogen deficiency-induced osteoporosis by suppressing RANKL-induced osteoclastogenesis. J Cell Mol Med. 2018; 23(1):380-394. PMC: 6307845. DOI: 10.1111/jcmm.13942. View

Ji J, Park-Min K, Shen Z, Fajardo R, Goldring S, McHugh K . Inhibition of RANK expression and osteoclastogenesis by TLRs and IFN-gamma in human osteoclast precursors. J Immunol. 2009; 183(11):7223-33. PMC: 2783334. DOI: 10.4049/jimmunol.0900072. View

10.

Chen X, Zhi X, Pan P, Cui J, Cao L, Weng W . Matrine prevents bone loss in ovariectomized mice by inhibiting RANKL-induced osteoclastogenesis. FASEB J. 2017; 31(11):4855-4865. PMC: 5636701. DOI: 10.1096/fj.201700316R. View

11.

Cho E, Lee J, Lee J, Chen Z, Ahn S, Kim N . BCPA {,'-1,4-Butanediylbis[3-(2-chlorophenyl)acrylamide]} Inhibits Osteoclast Differentiation through Increased Retention of Peptidyl-Prolyl Isomerase Never in Mitosis A-Interacting 1. Int J Mol Sci. 2018; 19(11). PMC: 6275020. DOI: 10.3390/ijms19113436. View

12.

Lee K, Chung Y, Ahn H, Kim H, Rho J, Jeong D . Selective Regulation of MAPK Signaling Mediates RANKL-dependent Osteoclast Differentiation. Int J Biol Sci. 2016; 12(2):235-45. PMC: 4737679. DOI: 10.7150/ijbs.13814. View

13.

Ahn S, Chen Z, Lee J, Lee S, Min S, Kim N . Inhibitory Effects of 2N1HIA (2-(3-(2-Fluoro-4-Methoxyphenyl)-6-Oxo-1(6H)-Pyridazinyl)--1H-Indol-5-Ylacetamide) on Osteoclast Differentiation via Suppressing Cathepsin K Expression. Molecules. 2018; 23(12). PMC: 6321589. DOI: 10.3390/molecules23123139. View

14.

Dempster D, Lambing C, Kostenuik P, Grauer A . Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data. Clin Ther. 2012; 34(3):521-36. DOI: 10.1016/j.clinthera.2012.02.002. View

15.

Lee K, Seo I, Choi M, Jeong D . Roles of Mitogen-Activated Protein Kinases in Osteoclast Biology. Int J Mol Sci. 2018; 19(10). PMC: 6213329. DOI: 10.3390/ijms19103004. View

16.

Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C . Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways. J Bone Miner Res. 2010; 26(3):644-56. DOI: 10.1002/jbmr.242. View

17.

Kearns A, Khosla S, Kostenuik P . Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2007; 29(2):155-92. PMC: 2528846. DOI: 10.1210/er.2007-0014. View

18.

Wang L, Liu S, Zhao Y, Liu D, Liu Y, Chen C . Osteoblast-induced osteoclast apoptosis by fas ligand/FAS pathway is required for maintenance of bone mass. Cell Death Differ. 2015; 22(10):1654-64. PMC: 4563780. DOI: 10.1038/cdd.2015.14. View

19.

Helfrich M . Osteoclast diseases. Microsc Res Tech. 2003; 61(6):514-32. DOI: 10.1002/jemt.10375. View

20.

Luo G, Li F, Li X, Wang Z, Zhang B . TNF‑α and RANKL promote osteoclastogenesis by upregulating RANK via the NF‑κB pathway. Mol Med Rep. 2018; 17(5):6605-6611. PMC: 5928634. DOI: 10.3892/mmr.2018.8698. View